Medicine occasionally delivers findings so counterintuitive that they force a reconsideration of assumptions that nobody realised they were making. The emerging evidence that routine vaccinations — against influenza, shingles, pneumococcal disease, and even the century-old BCG tuberculosis vaccine — may meaningfully reduce the risk of Alzheimer’s disease and other dementias qualifies as precisely that kind of finding. The hypothesis being advanced by a growing group of immunologists and neurologists is not a peripheral curiosity. If it withstands scrutiny, it would represent one of the most significant reframings of dementia aetiology in a generation.
The data trail begins with epidemiology. A series of large retrospective cohort studies conducted between 2021 and 2025, drawing on health records from populations in the United States, the United Kingdom, and South Korea, found consistent inverse associations between vaccination history and subsequent dementia diagnosis. The most striking figures come from the shingles vaccine literature: individuals who received the recombinant zoster vaccine — marketed as Shingrix — showed a reduction in dementia incidence of approximately 25 to 30 percent in some analyses, even after adjusting for confounders including socioeconomic status, baseline cognitive function, and access to healthcare. Similar but smaller signals emerged for influenza vaccination, where the protective association appeared to strengthen with each additional annual dose received.
The obvious first question is whether this is simply a healthy-user effect — the well-documented tendency of people who comply with vaccination recommendations to also engage in other health-protective behaviours, complicating causal inference. Researchers have worked hard to address this objection. A natural experiment emerged in Wales, where the shingles vaccine rollout was initially restricted by birth year cohort in a way that was effectively arbitrary from a health behaviour standpoint. Individuals just below the eligibility cutoff who received the vaccine showed significantly lower dementia rates than similar individuals just above the cutoff who did not — an instrumental variable design that is difficult to explain through healthy-user bias alone.
“The cohort eligibility cutoff is about as close to randomisation as you can get in a real-world setting,” said Professor Leila Mahmoud-Askar, a neuroepidemiologist at the University of Edinburgh whose group conducted one of the Welsh cohort analyses. “When you see the same signal in that design as you see in conventional observational data, the healthy-user explanation becomes harder to sustain.” Mahmoud-Askar is careful to note that correlation, however robust, is not causation, and that her group’s findings are awaiting independent replication before drawing firm clinical conclusions.
The mechanism being proposed is where the science becomes genuinely novel. The leading hypothesis invokes a phenomenon called trained immunity — the ability of the innate immune system, long assumed to lack immunological memory, to exhibit a form of functional reprogramming after exposure to certain pathogens or vaccines. Unlike the adaptive immune system’s antigen-specific memory, trained immunity operates through epigenetic modifications to monocytes and macrophages that alter their responsiveness for months or years. The proposal is that some vaccines trigger trained immunity programmes that enhance the brain’s microglial surveillance of amyloid and tau aggregates — the protein accumulations that are the pathological hallmarks of Alzheimer’s disease.
Microglia, the brain’s resident immune cells, are increasingly understood to play a central role in neurodegeneration. In healthy function, they clear cellular debris and monitor for early signs of protein misfolding. In the Alzheimer’s brain, they appear to shift into a dysfunctional state — sometimes too quiescent, sometimes chronically inflammatory — that accelerates rather than limits disease progression. The trained immunity hypothesis suggests that vaccines may recalibrate microglial baseline tone in ways that preserve their protective function longer into ageing.
“This is not a fringe idea anymore,” said Dr. Yusuf Al-Hammadi, a neurologist at Cleveland Clinic Abu Dhabi who follows the trained immunity literature closely. “The mechanistic evidence has moved from plausible to compelling in the last two years. What we need now is a prospective trial designed to actually test the hypothesis rather than reconstruct it retrospectively.” Several such trials are now in planning or early execution, including a multi-site study funded by a European research consortium that will randomise older adults to enhanced vaccination schedules and follow cognitive outcomes over five years.
The public health implications, even at the level of association rather than proven causation, are significant. Dementia affects an estimated 57 million people globally, with prevalence projected to nearly triple by 2050 as populations age. Existing pharmacological treatments for Alzheimer’s disease have shown modest effects at best in slowing progression and no effect on prevention. If a 25 percent reduction in incidence from routine vaccination were confirmed in prospective data, it would represent a larger population-level impact than any pharmacological intervention currently approved or in late-stage trials.
For health systems in the Gulf, which face rapidly ageing populations and are investing heavily in preventive care infrastructure, the trajectory of this research deserves close attention. Vaccination programmes that already exist and are cost-effective for their primary indications may carry a substantial neurological bonus. The startling thing is not that the immune system and the brain communicate — we have known for decades that they do. The startling thing is how much of the conversation we may have missed.